Subscribe

PharmaResearch Co., Ltd. (214450.KQ)

KRW309,000.00 -18,000.00 (-5.50%)
KR KOE Healthcare Medical - Pharmaceuticals
Address 77-19, Gwahakdanji-ro 25452
Gangneung-si, GG, KR
CEO Ji-Hoon Sohn
Website pharmaresearch.co.kr
IPO 2015-07-24
ISIN KR7214450009

Explore sections of this company profile

Description

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
KRW309,000.00 -18,000.00 (-5.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
107.8K
Beta
0.46
Float Shares
5.58M
Free Float %
53.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-5.64% -9.90% +2.48% -11.19% -28.77% -28.69% -22.24% +217.44% +339.63% +405.72% +170.31%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
309,000.00
DCF (Unlevered) 1,120,325.82 +262.6%
DCF (Levered) 1,710,236.99 +453.5%
Ratings Trend (MoM) 93% Bullish
Rating 2026-05 Change
Strong Buy 6 0
Buy 7 -1
Hold 1 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
9.03
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers ★ Strong MOAT
  • ✓
    Revenue growth Biotechnology: +1.5%
    +53.0% ★ Q1'26: +25.0% (vs Q1'25)
  • ✓
    EPS growth Biotechnology: +32.8%
    +83.7% ★ Q1'26: +39.3% (vs Q1'25)
  • ✓
    FCF margin Biotechnology: +15.5%
    +24.1% ★ Q1'26: +36.9% (vs Q1'25)
  • ✓
    EBIT margin Biotechnology: +0.0%
    +39.6% ★ Q1'26: +39.2% (vs Q1'25)
  • ✓
    ROIC Biotechnology: -18.9%
    +51.0% ★ Q1'26: +50.8% (vs Q1'25)
  • ✓
    Share dilution Biotechnology: -3.0%
    -1.6% ★ Q1'26: -7.9% (vs Q1'25)
  • ✓
    Debt / EBITDA Biotechnology: 0.15×
    0.94× Q1'26: 0.93× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.55) × ERP
WACC = 94% × Ke + 6% × Kd (4.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 1,127,838.75 Current price: 309,000.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
13 Rev. Ana.
14 EPS Ana. 		Dec 2027
14 Rev. Ana.
14 EPS Ana. 		Dec 2028
6 Rev. Ana.
7 EPS Ana. 		Dec 2029
9 Rev. Ana.
8 EPS Ana.
Revenue
37.45B
est: 38.42B (-2.5%)
45.95B
est: 53.90B (-14.7%)
54.47B
est: 54.59B (-0.2%)
64.28B
est: 75.30B (-14.6%)
83.87B
est: 80.60B (+4.1%)
108.75B
est: 108.85B (-0.1%)
154.08B
est: 151.65B (+1.6%)
194.76B
est: 191.60B (+1.6%)
261.01B
est: 261.92B (-0.3%)
350.12B
est: 346.89B (+0.9%)
535.72B
est: 540.66B (-0.9%)
670.45B
638.71B – 691.87B
+24.0% YoY
805.63B
744.27B – 873.28B
+20.2% YoY
935.71B
876.68B – 992.21B
+16.1% YoY
1.19T
1.12T – 1.26T
+27.3% YoY
EBITDA
17.39B
est: 15.60B (+11.5%)
18.41B
est: 21.89B (-15.9%)
16.15B
est: 22.17B (-27.2%)
20.19B
est: 30.58B (-34.0%)
29.54B
est: 32.73B (-9.8%)
41.79B
est: 44.20B (-5.5%)
66.21B
est: 61.58B (+7.5%)
76.52B
est: 77.81B (-1.7%)
115.01B
est: 106.36B (+8.1%)
134.09B
est: 143.76B (-6.7%)
228.14B
est: 224.06B (+1.8%)
277.84B
264.69B – 286.72B
+24.0% YoY
333.86B
308.44B – 361.90B
+20.2% YoY
387.77B
363.31B – 411.19B
+16.1% YoY
493.57B
462.43B – 523.38B
+27.3% YoY
EBIT
16.36B
est: 13.47B (+21.5%)
17.26B
est: 18.89B (-8.6%)
15.40B
est: 19.13B (-19.5%)
15.17B
est: 26.39B (-42.5%)
21.85B
est: 28.25B (-22.6%)
33.43B
est: 38.15B (-12.4%)
56.68B
est: 53.15B (+6.6%)
65.92B
est: 67.15B (-1.8%)
103.01B
est: 91.80B (+12.2%)
120.45B
est: 127.75B (-5.7%)
212.33B
est: 199.11B (+6.6%)
246.90B
235.22B – 254.79B
+24.0% YoY
296.68B
274.09B – 321.60B
+20.2% YoY
344.59B
322.85B – 365.40B
+16.1% YoY
438.60B
410.93B – 465.09B
+27.3% YoY
Net Income
12.88B
est: 14.93B (-13.7%)
13.91B
est: 20.90B (-33.4%)
12.96B
est: 20.98B (-38.2%)
14.41B
est: 28.20B (-48.9%)
16.67B
est: 21.32B (-21.8%)
32.77B
est: 36.20B (-9.5%)
46.69B
est: 53.35B (-12.5%)
40.58B
est: 54.49B (-25.5%)
76.55B
est: 86.93B (-11.9%)
92.04B
est: 93.11B (-1.1%)
165.12B
est: 167.77B (-1.6%)
203.41B
175.38B – 224.71B
+21.2% YoY
247.20B
207.67B – 298.60B
+21.5% YoY
265.75B
243.96B – 286.62B
+7.5% YoY
—
— – —
-100.0% YoY
SGA
7.35B
est: 9.95B (-26.1%)
7.95B
est: 13.95B (-43.0%)
7.50B
est: 14.13B (-46.9%)
10.32B
est: 19.49B (-47.1%)
10.50B
est: 20.86B (-49.7%)
28.30B
est: 28.18B (+0.4%)
42.45B
est: 39.25B (+8.1%)
58.86B
est: 49.60B (+18.7%)
74.41B
est: 67.80B (+9.8%)
59.96B
est: 85.15B (-29.6%)
103.55B
est: 132.72B (-22.0%)
164.57B
156.79B – 169.83B
+24.0% YoY
197.76B
182.70B – 214.36B
+20.2% YoY
229.69B
215.20B – 243.56B
+16.1% YoY
292.36B
273.91B – 310.01B
+27.3% YoY
EPS
1,687.48
est: 1,414.00 (+19.3%)
1,471.83
est: 1,979.00 (-25.6%)
1,386.28
est: 1,986.67 (-30.2%)
1,527.72
est: 2,671.00 (-42.8%)
1,766.04
est: 2,019.00 (-12.5%)
3,447.46
est: 3,428.50 (+0.6%)
4,716.62
est: 5,052.50 (-6.6%)
4,067.47
est: 5,160.75 (-21.2%)
7,571.00
est: 8,233.20 (-8.0%)
8,983.69
est: 8,961.03 (+0.3%)
16,420.00
est: 16,147.71 (+1.7%)
19,577.41
16,879.64 – 21,627.69
+21.2% YoY
23,791.66
19,987.38 – 28,739.57
+21.5% YoY
25,577.78
23,480.07 – 27,585.80
+7.5% YoY
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-08 A- 4/5 5/5 5/5 5/5 2/5 2/5 1/5
2026-05-07 A- 4/5 5/5 5/5 5/5 2/5 2/5 1/5
2026-05-06 A- 4/5 5/5 5/5 5/5 2/5 2/5 1/5
2026-05-04 A- 4/5 5/5 5/5 5/5 2/5 2/5 1/5
2026-04-30 A- 4/5 5/5 5/5 5/5 2/5 2/5 1/5
2026-04-29 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-28 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-27 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-24 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-23 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-22 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-21 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-20 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-17 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-16 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-15 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-14 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-13 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5
2026-04-10 B+ 3/5 5/5 5/5 5/5 1/5 2/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
245.12B
OE per share TTM
21,298.18
Owner's Yield
6.32%
Maintenance CapEx ratio
37.05%
Maint CapEx / Avg PPE
49.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
403.66M
Shares Outstanding
10.39M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Sang-Soo Jung Chief Executive Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals